Executive Control, Processing Speed and Memory Function in Long- Term Peripheral Neuropathic Pain and Fibromyalgia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Working Memory Deficits
- Sponsor
- Oslo University Hospital
- Enrollment
- 82
- Locations
- 1
- Primary Endpoint
- Objective neuropsychological tests
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The goal of this project is to investigate and improve executive control function in two distinct pain conditions, namely neuropathic pain and fibromyalgia (FM). It is hypothesized that there is a significant difference in the executive control function of patients with neuropathic pain and FM pain. It is also hypothesized that all participants with poor executive control functioning will report significant improvements in pain intensity, functioning and cognitive complaints following cognitive training. The study tests and influence the working memory concepts of inhibition, updating and flexibility through an experimental, cross-over treatment design.
To perform the experiment, we will recruit 160 participants (80 with neuropathic pain and 80 with FM) from the Departments of pain management and research at St Olav's University Hospital and Oslo University Hospital (OUS). The proposed design will be able to determine whether or not executive control, processing speed and memory function differs in two distinct populations of pain patients. Moreover, whether impairments are amended by computerized training.
Investigators
Henrik Børsting Jacobsen
Post Doctoral Fellow
Oslo University Hospital
Eligibility Criteria
Inclusion Criteria
- •Confirmed diagnosis of fibromyalgia or neuropathic pain
- •Confirmed objective cognitive impairments on the CANTAB battery compared to IQ control
Exclusion Criteria
- •Mania, suicidal ideation and/or active psychosis
- •No objective cognitive impairments
- •Personality disorders
- •Pregnancy
Outcomes
Primary Outcomes
Objective neuropsychological tests
Time Frame: 36 weeks
CANTAB test battery
Secondary Outcomes
- Sleep duration, quality and awakening(36 weeks)
- Quality of life(36 weeks)
- Medication use(36 weeks)
- Stress regulation(36 weeks)
- Self-reported memory and concentration impairments(36 weeks)
- Pain intensity(36 weeks)
- Symptoms of depression(36 weeks)
- Self-reported cognitive intrusion(36 weeks)